Despite the recent sell-off in tech stocks, analysts at Wedbush believe that this downturn is temporary and that AI leaders ...

Investment analysts at Wedbush boosted their FY2025 earnings estimates for shares of Fennec Pharmaceuticals in a research ...

Voyager Therapeutics (NASDAQ:VYGR – Get Free Report)‘s stock had its “outperform” rating reissued by analysts at Wedbush in a ...

Fintel reports that on March 12, 2025, Wedbush downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Outperform to ...

As previously reported, Wedbush analyst Robert Driscoll downgraded Arvinas (ARVN) to Neutral from Outperform with a price target of $12, down ...

Market fears over tariffs and growth have hit tech stocks, but Wedbush sees the dip as a buying opportunity for long-term investors ...

Dan Ives, Wedbush Securities global head of technology research, joins CNBC's 'Squawk on the Street' to discuss outlooks on ...

Despite the recent rash of tech stock sell-offs, the analysts at Wedbush believe this is a short-term phenomenon, and the ...

Wedbush analysts called Palantir one of their "top names" to own in 2025, expecting the stock to benefit from a "tidal wave of spending on AI." ...

Markets are still under a great deal of pressure. All thanks to more tariffs on Canada, Mexico, China and inflation threats, ...

Elon Musk’s role in the Trump administration is complicating his business ventures, as the tech billionaire pushes forward with efforts to slash the federal government and budget in the face of ...